13 biotech investors back Hong Kong startups in 2026. LAV, OrbiMed, and Qiming fund drug discovery. HK Science Park hosts over 300 biomedical firms.
Hong Kong is a major Asian biotech funding hub. Its rules let pre-revenue biotechs list on HKEX.
LAV and OrbiMed back the bigger clinical rounds. HKSTP nurtures many of the earliest biotech teams.
These funds want strong data and a clear clinical path. Ellty tracks every open when you share your deck.
This guide lists 13 active Hong Kong biotech investors.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Lilly Asia Ventures | Life-sciences VC | US$10M-$100M | Biopharma, devices, diagnostics | lavfund.com |
| OrbiMed | Healthcare investor | US$10M-$100M | Biotech, pharma, medtech | orbimed.com |
| Qiming Venture Partners | Top China VC | US$5M-$50M | Biotech, medtech, healthcare | qimingvc.com |
| HongShan | China venture firm | US$5M-$100M+ | Healthcare, biotech, tech | hongshan.com |
| Hillhouse / GL Ventures | Early-stage VC arm | US$10M-$150M | Biotech, healthcare, tech | hillhouseinvestment.com |
| Vivo Capital | Healthcare investor | US$10M-$100M | Biotech, pharma, medtech | vivocapital.com |
| CBC Group | Healthcare PE / VC | US$20M-$200M+ | Biotech, medtech, services | cbridgecap.com |
| 6 Dimensions Capital | Cross-border healthcare VC | US$5M-$50M | Biotech, pharma, diagnostics | 6dimensionscapital.com |
| Horizons Ventures | Deep-science VC | US$5M-$50M | Biotech, deep science | horizonsventures.com |
| Morningside Venture Capital | Private investment group | US$5M-$50M | Biotech, life sciences | morningside.com |
| HKSTP | Govt innovation hub | Grants + CVF co-invest | Biotech, therapeutics, medtech | hkstp.org |
| HKIC | Govt investment arm | Large strategic stakes | Biotech, life sciences, deep tech | hkic.hk |
| ClavystBio | Asia biotech investor | US$5M-$30M | Biotech, therapeutics, drug discovery | clavystbio.com |
Run your Hong Kong biotech raise tight
Biotech VCs dig into your trial data and IP fast. Ellty logs every view in your data room.
Start free 14-day trialWhat a biotech investor backs
A biotech investor backs drugs and diagnostics. In Hong Kong that means strong, clean clinical data.
Most write big cheques into clinical-stage firms. Founders pitching Hong Kong AI investors face it too.
They study your trial data, IP, and regulatory path. Protect your sensitive IP with strong security.
Ellty gives each fund one trackable link to your data room. You see who studied your trial data before the call.
Chinese companies just got out of the biology winter, and the market has returned to a stable footing.
13 Hong Kong biotech investors
1. Lilly Asia Ventures
LAV is a life-sciences VC spun out of Eli Lilly.
Recent Activity: Closed Fund VII at a US$700M hard cap and backed Pulnova
LinkedIn: Lilly Asia Ventures LinkedIn
Sector Focus: Biopharma, devices, diagnostics
Stage Focus: Series A to growth
Check Size: US$10M-$100M
Location: Shanghai / Hong Kong
Website: lavfund.com
2. OrbiMed
OrbiMed is a global healthcare investor with an Asia fund.
Recent Activity: Raised about US$751M for OrbiMed Asia Partners V
LinkedIn: OrbiMed LinkedIn
Sector Focus: Biotech, pharma, medtech
Stage Focus: Series A to growth
Check Size: US$10M-$100M
Location: New York / Hong Kong
Website: orbimed.com
3. Qiming Venture Partners
Qiming is a top China VC with a big biotech arm.
Recent Activity: Backs Greater China biopharma like InventisBio
LinkedIn: Qiming Venture Partners LinkedIn
Sector Focus: Biotech, medtech, healthcare
Stage Focus: Seed to Series C
Check Size: US$5M-$50M
Location: Shanghai / Hong Kong
Website: qimingvc.com
4. HongShan
HongShan is the China firm split from Sequoia.
Recent Activity: Backs Greater China healthcare and biotech rounds
LinkedIn: HongShan LinkedIn
Sector Focus: Healthcare, biotech, tech
Stage Focus: Seed to growth
Check Size: US$5M-$100M+
Location: Hong Kong / Beijing
Website: hongshan.com
5. Hillhouse / GL Ventures
GL Ventures is Hillhouse's early-stage VC arm.
Recent Activity: Led a US$147M Series D for the biotech InventisBio
LinkedIn: Hillhouse LinkedIn
Sector Focus: Biotech, healthcare, tech
Stage Focus: Early stage to growth
Check Size: US$10M-$150M
Location: Hong Kong / Beijing
Website: hillhouseinvestment.com
Share your trial data and track every biotech VC
Ellty shows when LAV or OrbiMed opens your data. Follow up with each biotech fund at the right time.
Start free 14-day trial6. Vivo Capital
Vivo Capital is a US and China healthcare investor.
Recent Activity: Closed a US$740M public-market strategy in 2025
LinkedIn: Vivo Capital LinkedIn
Sector Focus: Biotech, pharma, medtech
Stage Focus: Clinical-stage, growth
Check Size: US$10M-$100M
Location: Palo Alto / Shanghai
Website: vivocapital.com
7. CBC Group
CBC Group is one of Asia's largest healthcare funds.
Recent Activity: Builds healthcare platforms across pharma and medtech
LinkedIn: CBC Group LinkedIn
Sector Focus: Biotech, medtech, services
Stage Focus: Growth, buyout
Check Size: US$20M-$200M+
Location: Shanghai / Hong Kong
Website: cbridgecap.com
8. 6 Dimensions Capital
6 Dimensions is a cross-border healthcare VC.
Recent Activity: Backs Greater China pharma and diagnostics firms
LinkedIn: 6 Dimensions Capital LinkedIn
Sector Focus: Biotech, pharma, diagnostics
Stage Focus: Early stage to growth
Check Size: US$5M-$50M
Location: Shanghai / Hong Kong
Website: 6dimensionscapital.com
9. Horizons Ventures
Horizons is a Li Ka-shing-linked deep-science VC.
Recent Activity: A long-standing backer of Insilico Medicine
LinkedIn: Horizons Ventures LinkedIn
Sector Focus: Biotech, deep science
Stage Focus: Early stage, Series A-B
Check Size: US$5M-$50M
Location: Hong Kong
Website: horizonsventures.com
10. Morningside Venture Capital
Morningside has a long China biotech practice.
Recent Activity: Co-invests in China biotech with Qiming and OrbiMed
LinkedIn: Morningside LinkedIn
Sector Focus: Biotech, life sciences
Stage Focus: Early stage to growth
Check Size: US$5M-$50M
Location: Hong Kong / Shanghai
Website: morningside.com
11. HKSTP
HKSTP runs Hong Kong's biomedical innovation hub.
Recent Activity: Hosts 300+ life-and-health firms at Science Park
LinkedIn: HKSTP LinkedIn
Sector Focus: Biotech, therapeutics, medtech
Stage Focus: Incubation, seed
Check Size: Grants plus CVF co-invest
Location: Hong Kong
Website: hkstp.org
12. HKIC
HKIC is the Hong Kong government's investment arm.
Recent Activity: Backed Insilico Medicine in a 2025 strategic deal
LinkedIn: Not listed
Sector Focus: Biotech, life sciences, deep tech
Stage Focus: Growth, strategic
Check Size: Large strategic stakes
Location: Hong Kong
Website: hkic.hk
13. ClavystBio
ClavystBio is a Temasek-linked Asia biotech investor.
Recent Activity: Backed Allay Therapeutics' US$57.5M Series D
LinkedIn: ClavystBio LinkedIn
Sector Focus: Biotech, therapeutics, drug discovery
Stage Focus: Seed to Series B
Check Size: US$5M-$30M
Location: Singapore / Asia-focused
Website: clavystbio.com
Drug discovery and AI biotech
Hong Kong leads in AI-driven drug discovery now. Insilico runs much of its drug research from here.
Funds want strong data and a real clinical path. A nice idea with no real data will rarely raise.
Show your trial results and your full IP position. Keep it all in one single clean virtual data room.
See how a data room for biotech deals works. Ellty logs exactly who opened each file and when.
Medtech and diagnostics
Medtech and diagnostics grow fast in Hong Kong. The Science Park backs many of these young firms.
Funds want approvals and a clear reimbursement path. A device with no real clinical data will not raise.
Show your approvals, trials, and unit economics. Run clean due diligence well before any big round.
Messy regulatory records lose biotech VCs fast. Ellty shows who read your data and exactly when.
Listing on HKEX 18A
Hong Kong lets pre-revenue biotechs list early. Its Chapter 18A first opened that door in 2018.
A public listing can follow a strong private round. Insilico's 2025 IPO was a big, recent local example.
Keep all your records clean for the listing path. Get your whole fundraising process tight early on.
Set up a data room for your Series A round early. Ellty tracks who reads each file you send.
How to pitch a biotech investor
Lead with data, IP, and a clear clinical path.
- 1.Show strong trial data and clean IP.Biotech VCs fund data, not just hope.
- 2.Lay out a clear path through the clinic.A vague plan stalls biotech rounds.
- 3.Share one Ellty link to your data room.Track who opens it and which files.
- 4.Follow up the moment a fund digs in.Ellty tells you exactly when they do.
How Ellty helps you land a biotech investor in Hong Kong
You've shortlisted your Hong Kong biotech investors already. Set up a data room before the first call.
- 1.Upload your trial data, IP, and deck.Set access per fund or per partner.
- 2.Share one trackable link with each fund.Each fund gets its own tracked link.
- 3.Watch opens and follow up at the right time.Use Ellty analytics to time each nudge.
Hong Kong biotech investor questions
- LAV and OrbiMed back clinical rounds. HKSTP nurtures the earliest teams.
- Cheques run US$5M to US$200M in 2026. Clinical rounds run very large.
- Strong trial data and clean IP. A clear clinical path also helps.
- Its HKEX 18A rule helps biotechs list. Science Park hosts 300+ firms.
- It lets pre-revenue biotechs list early. Many have used it since 2018.
- Before your first biotech call. Track who opens your trial data.
